AstraZeneca
AZN
401 hedge funds and large institutions have $5.76B invested in AstraZeneca in 2014 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 126 increasing their positions, 145 reducing their positions, and 52 closing their positions.
60% more call options, than puts
Call options by funds: $1.12B | Put options by funds: $702M
1.52% less ownership
Funds ownership: 7.91% → 6.39% (-1.5%)
4% less funds holding
Funds holding: 418 → 401 (-17)
13% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 145
23% less capital invested
Capital invested by funds: $7.43B → $5.76B (-$1.67B)
23% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 52
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$88.4M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$49.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$43.4M |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$32.6M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$31.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Mason Capital Management
New York
|
-$249M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$239M |
| 3 |
Jane Street
New York
|
-$127M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$123M |
| 5 |
OCAM
Owl Creek Asset Management
New York
|
-$111M |
AZN Hedge Fund Activity: Q3 2014 in Review
401 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2014, worth a combined $5.76B — down 23% from $7.43B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of AZN and 40 opened new positions — a net loss of 12 holders — while 145 trimmed existing stakes and 126 added.
The largest buyer was Arrowstreet Capital, adding an estimated $88.4M. The largest seller was Mason Capital Management, exiting entirely with an estimated $249M sold.
- 401 institutional investors held AstraZeneca (AZN) as of Q3 2014, down from 418 in Q2 2014.
- Funds reported $5.76B of AstraZeneca stock for Q3 2014, down 23% quarter-over-quarter.
- 40 funds opened new AstraZeneca positions in Q3 2014 and 52 closed out, a net change of -12 holders.
- The largest AstraZeneca buyer in Q3 2014 was Arrowstreet Capital, an estimated $88.4M added.
- The largest AstraZeneca seller in Q3 2014 was Mason Capital Management, an estimated $249M sold.
Based on aggregated 13F filings for Q3 2014.